Results 241 to 250 of about 149,286 (348)

Structural Characterization and AI‐Enhanced Modeling of a Broadly Neutralizing Camelid Antibody Against SARS‐CoV‐2 Variants

Advanced Therapeutics, Volume 9, Issue 1, January 2026.
This study characterizes a camelid antibody (B10) with potent neutralizing activity against SARS‐CoV‐2 Wildtype and Omicron variants. Through binding assays, epitope mapping, pseudovirus neutralization, and AI‐driven modeling, the antibody is shown to target conserved RBD regions in a closed Spike conformation.
Katja Hanack, Urszula Orzeł, Anja Schlör, Sourabh Mehta, Anandi Krishnan, Slawomir Filipek, Rushika Patel, Madhvi Joshi, Markus Hoffmann, Stefan Pöhlmann, Chaitanya Joshi, Dorian Liepmann, Ramasamy Paulmurugan, Venkatesan Renugopalakrishnan   +13 more
wiley   +1 more source

Garlic-Derived Phytochemical Candidates Predicted to Disrupt SARS-CoV-2 RBD–ACE2 Binding and Inhibit Viral Entry [PDF]

M. García‐Delgado, Aldo Herrera-Rodulfo, Karen Y. Reyes‐Melo, Alladi Mohan, Fernando Góngora‐Rivera, Jesús Pedroza-Flores, Alma D. Paz-González, Gildardo Rivera, María del Rayo Camacho‐Corona, Mauricio Carrillo‐Tripp   +9 more
openalex   +1 more source

Evaluation of Antigen Expression and Early Immune Response Following Cutaneous Suction‐Mediated DNA Delivery

Advanced Therapeutics, Volume 9, Issue 1, January 2026.
In vivo suction‐based cutaneous DNA vaccination promotes robust immunogenic responses. The spatiotemporal patterns of antigen expression following suction‐based SARS‐CoV‐2 DNA vaccine delivery are evaluated in rat skin via immunofluorescence staining.
Nandita C. Jhumur, Yukyung Um, Sarah H. Park, Emran O. Lallow, Christine C. Roberts, Jerry W. Shan, Jonathan P. Singer, Jeffrey D. Zahn, Young K. Park, Lisa K. Denzin, David I. Shreiber, Joel N. Maslow, Hao Lin   +12 more
wiley   +1 more source

A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

, 2020
Murat Öz, Dietrich E. Lorke, Nadine Kabbani   +2 more
openalex   +2 more sources

Human ACE2 ELISA v1

The COVID-19pandemic has led to a significant number of individuals experiencing persistentpost-acute sequelae, commonly referred to as long COVID, following SARS-CoV-2infection. Similar symptoms, though less frequent, have also been observedafter COVID-19 vaccination.
openaire   +1 more source

Inducible T‐Cell Co‐Stimulator (ICOS) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Cancer Medicine, Volume 15, Issue 1, January 2026.
ICOS (inducible T‐cell co‐stimulator) and ICOS ligand (ICOSL) are part of an important, complex pathway that can lead to both immune stimulation and suppression. Both ICOS agonists and antagonists are under development as oncology therapeutics and biomarker driven approaches will be important to ascertain which patients will derive the greatest benefit
Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary K. Nesline, Heidi Ko, Jeffrey M. Conroy, Aung Naing, Razelle Kurzrock   +9 more
wiley   +1 more source

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

European journal of internal medicine, 2020
P. Verdecchia, C. Cavallini, A. Spanevello, F. Angeli   +3 more
semanticscholar   +1 more source

Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation

, 2022
Anthony J. Turner, Natalia N. Nalivaeva
openalex   +2 more sources

ACE2 wt Allele [PDF]

, 2020
openaire   +1 more source

Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas

ChemMedChem, Volume 21, Issue 1, January 2026.
Structure of the "hit‐compound" found and the proposed interaction with the active site of the TMPRSS2 protease, involving a reversible mechanism of action, are shown. The COVID‐19 pandemic highlighted the urgent need for effective antiviral treatments targeting SARS‐CoV‐2.
Marco Minneci, Barbara Farkaš, Adeyemi Rahman, Amy Kempf, Inga Nehlmeier, Stefan Pöhlmann, Isabel Rozas   +6 more
wiley   +1 more source